Stay updated with breaking news from Nasdaq Pali. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Maxim Group reissued their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a report released on Wednesday, Benzinga reports. Maxim Group currently has a $22.50 price objective on the stock. Palisade Bio Price Performance NASDAQ:PALI opened at $7.08 on Wednesday. The company’s 50 day moving average is $5.70 and its 200-day […]
Maxim Group restated their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $22.50 price target on the stock. Palisade Bio Price Performance Shares of Palisade Bio stock opened at $4.71 on Tuesday. Palisade Bio has a 1 […]
Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, an increase of 1,450.4% from the January 15th total of 129,000 shares. Currently, 25.7% of the company’s stock are short sold. […]
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology,...
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company...